GSK closes on approval of asthma hope depemokimab GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.

#GSK #depemokimab #severeasthma #Exdensur #CRSwNP #respiratory #immunology #inflammation #Nucala #mepolizumab #COPD #rarediseases #SerumLifeScienceEurope #Anktiva #NMIBC #SFLPharma #Aumseqa #NSCLC #Cytokinetics #Myqorzo #hypertrophiccardiomyopathy #Moderna #Mnexspike #COVID19vaccine
zurl.co/l8WfN

GSK "well positioned" to weather pharma tariffs GSK has said it is not too worried about the impact of potential pharma-specific US tariff rules as it posts a solid set of first-quarter results

#GSK #pharmatariffs #PharmaNews #financialresults #pharmaspecificUStariffrules #UStariffrules #vaccines #specialtymedicines #severeasthmatherapy #shinglesvaccine #RSV #COPD #asthmabiologic #depemokimab #biologics #meningitisvaccine #antibiotics
pharmaphorum.com/news/gsk-wel...

Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials Depemokimab significantly improved clinically relevant coprimary endpoints versus placebo and was well tolerated, supporting its use as a twice per year treatment option, with the potential to reduce ...

My personal highlights:presentation of ANCHOR 1/2 studies investigating the effect of #depemokimab...

www.thelancet.com/journals/lan...

#medsky #immunology 🧪 #AAAAI

(2/3)